home

Commense Advances Microbiome Platform Targeting Early Childhood Health

R&Dpure tech health2016-04-01 09:20 Read   89

Commense, focused on preventing and treating disease through microbiome-based interventions in infancy and early childhood, advances its discovery and development platform, names its founding scientists and advisors and executes an exclusive license in the microbiome field. 

ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review

R&DBUSINESS WIRE2016-03-31 11:24 Read   146

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is reducing approximately 25 percent of its headquarter positions.

SANOFI APPOINTS DR. YONG-JUN LIU AS HEAD OF RESEARCH

R&DSANOFI2016-03-30 09:42 Read   121

Paris, France - March 29, 2016 - Sanofi announced today the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D, effective April 1, 2016. He will report to Dr. Elias Zerhouni, President, Global R&D.

UPDATED: FDA AdComm experts acknowledge problems, but give a thumbs-up on Acadia's Parkinson's antipsychotic

R&DFiercebiotech2016-03-30 09:31 Read   142

An FDA advisory panel of outside experts weighed the data on the risks and potential benefits of using Acadia's ($ACAD) Nuplazid (pimavanserin) as a new antipsychotic for Parkinson's patients, and most concluded that it should be OK'd for commercial use at this point.

Alexza Reports Fourth Quarter and Year End 2015 Financial Results

R&DPR newswire2016-03-30 09:15 Read   108

lexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company") today reported financial results for the quarter and year ended December 31, 2015.

West Coast Bio Roundup: Gilead, Affymetrix, Acutus, Frazier & More

R&DXconomy2016-03-28 10:38 Read   93

Gilead Sciences is back at the top of our chart for the second week in a row. After halting trials last week in the United States and Europe over its cancer drug idelalisib, a federal jury in San Jose, CA, upheld the validity of two Merck patents this week in a case that could force Gilead to turn over billions.

AZ's Brilinta disappoints in stroke trial

R&DPMLIVE2016-03-28 10:09 Read   133

AstraZeneca's antiplatelet drug Brilinta has joined the long list of drugs that have failed to show a significant benefit suffering an ischaemic stroke.

AstraZeneca stroke trial fails to hit target

R&DAstraZeneca2016-03-26 07:13 Read   85

AstraZeneca’s Brilinta has missed its targets in a Phase III trial assessing the blood thinner in patients with acute ischaemic stroke or transient ischaemic attack.

Roche CEO Schwan beats Novartis chief with $12.3M in 2015 pay, but U.S. companies shell out more

R&DRoche2016-03-25 10:48 Read   194

Roche ($RHHBY) CEO Severin Schwan's total pay for 2015 didn't change much from the previous year: In both instances, he totted up almost 12 million Swiss francs, or $12.3 million at current exchange rates.

Valeant begins search for new CEO

R&DPMLIVE2016-03-25 10:16 Read   112

Valeant has begun the search for a new chief executive officer to succeed Michael Pearson who is stepping down, but has promised to continue until his replacement is appointed.

Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration

R&DAmgen2015-11-27 13:49 Read   567

Amgen today announced the submission of a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501, a biosimilar candidate to Humira® (adalimumab).

Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

R&DIsis2015-11-06 14:37 Read   594

Trial marks second study for volanesorsen in a rare, genetic lipid disorder